期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

绝经后激素受体阳性乳腺癌患者辅助内分泌治疗的策略选择 被引量：4

原文传递
导出
摘要 乳腺癌是我国女性发病率最高的恶性肿瘤,其治疗除了手术、放化疗等治疗措施外,对于激素受体阳性的早期乳腺癌患者内分泌治疗也是有效的治疗选择。近年来,随着许多大规模临床试验报道证实了芳香化酶抑制剂(AI)在辅助治疗中价值,对于绝经后激素受体阳性的乳腺癌患者的辅助内分泌治疗,AI正在逐渐取代他莫昔芬(TAM)。
作者 周力恒 邵志敏
机构地区 复旦大学附属肿瘤医院乳腺外科
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第10期652-654,共3页 National Medical Journal of China
关键词 辅助内分泌治疗 乳腺癌患者 激素受体 绝经后 阳性 芳香化酶抑制剂 临床试验报道 恶性肿瘤
分类号 R737.9 [医药卫生—肿瘤]
作者简介 通信作者:邵志敏,Email:zhimingshao@yahoo.com
  • 相关文献

参考文献15

  • 1余之刚.应重视我国乳腺癌的预防[J].中华医学杂志,2010,90(8):505-507. 被引量：26
  • 2姚舒洋,徐兵河,李青,张频,王佳玉,袁芃,马飞,蔡瑞刚.戈舍瑞林联合阿那曲唑治疗晚期绝经前乳腺癌的临床观察[J].中华医学杂志,2010,90(8):526-528. 被引量：16
  • 3Ingle JN, Tu D, Pater JL, et al . Intent-to-treat analysis of the placebo-controlled trim of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA. 17. Ann 0ncol,2008, 19: 877 -882.
  • 4Mansell J, Monypenny IJ, Skene AI, et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat,2009, 117:91-98.
  • 5CuzickJ, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer ,2006,94:460-464.
  • 6Del Mastro LM. Venturini ATAC trial update. Lancet,2005,365 : 1225 ; author reply 1226.
  • 7Thurlimann B, Keshaviah A, Coates AS, et al . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med,2005, 353:2747-2757.
  • 8Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med,2009, 361:766-776.
  • 9Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 2002, 359 : 2131- 2139.
  • 10Howell A, Cuzick J, Baum M, et al . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination ) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet,2005, 365:60-62.

二级参考文献57

  • 1江泽飞,姚开泰,宋三泰.乳腺癌治疗的新循证医学证据和临床实践[J].中华医学杂志,2005,85(43):3025-3027. 被引量：29
  • 2宋传贵,胡震,袁文涛,狄根红,沈镇宙,黄薇,邵志敏.上海地区早发性乳腺癌患者BRCA1和BRCA2基因突变分析[J].中华医学杂志,2005,85(43):3030-3034. 被引量：26
  • 3杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量：281
  • 4Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002.CA Cancer J Clin,2005,55:74-108.
  • 5Landis SH,Murray T,Bolden S,et al.Cancer statistics,1999.CA Cancer J Clin,1999,49:8-31.
  • 6Greeaberg PA,Hortobagyi GN,Smith TL,et al.Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.J Clin Oncol,1996,14:2197-2205.
  • 7Forward DP,Cheung KL,Jackson L,et al.Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.Br J Cancer,2004,90:590-594.
  • 8Carlson RW,Schurman CM,Rivera E,et al.Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive,recurrent/metastatic breast cancer.Breast Cancer Res Treat,2004,88:S237.
  • 9Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada.J Nail Cancer Inst,2000,92:205-216.
  • 10De Maio E,Gravina A,Pacilio C,et al.Compliance and toxicity of adjuvant CMF in elderly breast cancer patients:a single-center experience.BMC Cancer,2005,5:30.

共引文献49

同被引文献44

  • 1徐迎春,林玉梅,张凤春.乳腺癌内分泌治疗耐药机制研究进展[J].中华肿瘤防治杂志,2006,13(3):227-231. 被引量：8
  • 2Orlando L, Schiavone P, Fedele P, et al. Molecularly targetedendocrine therapies for breast cancer. Cancer Treat Rev, 2010,36:S67-71.
  • 3Helleman J, Jansen MP, Ruigrok-Ritstier K, et al. Association ofan extracellular matrix gene cluster with breast cancer prognosisand endocrine therapy response. Clin Cancer Res,2008,14 :5555-5564.
  • 4Generali D, Berruti A, Brizzi MP, et al. Hypoxia-induciblefactor-1 a expression predicts a poor response to primarychemoendocrine therapy and disease-free survival in primaryhuman breast cancer. Clin Cancer Res, 2006, 12:4562-4568.
  • 5Mita MM, Mita A, Rowinsky EK. Mammalian target ofrapamycin : a new molecular target for breast cancer. Clin BreastCancer, 2003,4:126-137.
  • 6Osborne CK,Schiff R. Mechanisms of endocrine resistance inbreast cancer . Annu Rev Med, 2011,62:233-247.
  • 7Miller WR. Identification and mechanisms of endocrine resistance.Breast Cancer Res, 2008 , 10:S19.
  • 8Alkner S, Bendahl PO, Grabau D, et al. AIB1 is a predictivefactor for tamoxifen response in premenopausal women. AnnOncol, 2010,21:238-244.
  • 9Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plusanastrozole versus anastrozole alone for the treatment ofpostmenopausal women with human epidermal growth factorreceptor 2-positive, hormone receptor-positive metastatic breastcancer: results from the randomized phase HI TAnDEM study. JClin Oncol,2009,27:5529-5537.
  • 10Schwartzberg LS, Franco SX, Florance A, et al. Lapatinib plusletrozole as flrstline therapy of Her-2 + hormone receptor-positivemetastatic breast cancer. Oncologist, 2010,15: 122-129.

引证文献4

二级引证文献2

中华医学杂志
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部